This ferroptotic phenotype was ameliorated by anti-ferroptotic compounds, iron chelators, and HO-1 inhibitors, which alleviated lung inflammation and the destruction and remodeling of COPD, representing a potential target (Figure 8). Here, HMOX1 is linked to chronic obstructive pulmonary disease.